10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AC Immune Ltd
Buy, Hold or Sell?

Let's analyze AC Immune Ltd together

I guess you are interested in AC Immune Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AC Immune Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AC Immune Ltd

I send you an email if I find something interesting about AC Immune Ltd.

Quick analysis of AC Immune Ltd (30 sec.)










What can you expect buying and holding a share of AC Immune Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.6%

What is your share worth?

Current worth
$1.65
Expected worth in 1 year
$1.55
How sure are you?
31.6%

+ What do you gain per year?

Total Gains per Share
$-0.10
Return On Investment
-2.6%

For what price can you sell your share?

Current Price per Share
$3.91
Expected price per share
$3.42 - $5.14
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of AC Immune Ltd (5 min.)




Live pricePrice per Share (EOD)

$3.91

Intrinsic Value Per Share

$4.75 - $6.04

Total Value Per Share

$6.40 - $7.69

2. Growth of AC Immune Ltd (5 min.)




Is AC Immune Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$163.8m$202.3m-$40.9m-25.3%

How much money is AC Immune Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$15.4m-$19.6m$4.2m27.2%
Net Profit Margin-8.0%-468,810.9%--

How much money comes from the company's main activities?

3. Financial Health of AC Immune Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#288 / 982

Most Revenue
#368 / 982

Most Profit
#652 / 982

Most Efficient
#341 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of AC Immune Ltd? (5 min.)

Welcome investor! AC Immune Ltd's management wants to use your money to grow the business. In return you get a share of AC Immune Ltd.

What can you expect buying and holding a share of AC Immune Ltd?

First you should know what it really means to hold a share of AC Immune Ltd. And how you can make/lose money.

Speculation

The Price per Share of AC Immune Ltd is $3.91. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AC Immune Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AC Immune Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.65. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AC Immune Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-5.2%-0.16-4.0%-0.20-5.0%-0.17-4.3%-0.08-2.0%
Usd Book Value Change Per Share-0.19-4.9%-0.03-0.7%-0.18-4.5%-0.06-1.4%0.041.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-4.9%-0.03-0.7%-0.18-4.5%-0.06-1.4%0.041.1%
Usd Price Per Share2.96-3.44-2.79-4.94-5.62-
Price to Earnings Ratio-3.64--8.65--3.63--6.91--41.91-
Price-to-Total Gains Ratio-15.51--10.05--17.67--23.90--31.04-
Price to Book Ratio1.80-2.09-1.35-2.09-3.11-
Price-to-Total Gains Ratio-15.51--10.05--17.67--23.90--31.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.91
Number of shares255
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.03-0.06
Usd Total Gains Per Share-0.03-0.06
Gains per Quarter (255 shares)-6.54-14.29
Gains per Year (255 shares)-26.17-57.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-26-360-57-67
20-52-620-114-124
30-79-880-171-181
40-105-1140-229-238
50-131-1400-286-295
60-157-1660-343-352
70-183-1920-400-409
80-209-2180-457-466
90-236-2440-514-523
100-262-2700-572-580

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%8.030.00.021.1%8.030.00.021.1%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%12.024.02.031.6%12.024.02.031.6%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.037.02.6%1.00.037.02.6%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%12.024.02.031.6%12.024.02.031.6%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of AC Immune Ltd

About AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Fundamental data was last updated by Penke on 2024-07-09 02:19:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of AC Immune Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit AC Immune Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AC Immune Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-8.0%+8.0%
TTM-8.0%YOY-468,810.9%+468,802.9%
TTM-8.0%5Y-94,161.1%+94,153.0%
5Y-94,161.1%10Y-49,844.5%-44,316.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.6%+168.6%
TTM-8.0%-209.9%+201.9%
YOY-468,810.9%-235.1%-468,575.8%
5Y-94,161.1%-390.8%-93,770.3%
10Y-49,844.5%-505.1%-49,339.4%
1.1.2. Return on Assets

Shows how efficient AC Immune Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -10.7% Return on Assets means that AC Immune Ltd generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AC Immune Ltd:

  • The MRQ is -10.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.7%TTM-8.7%-2.0%
TTM-8.7%YOY-9.0%+0.4%
TTM-8.7%5Y-7.1%-1.6%
5Y-7.1%10Y-2.5%-4.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-11.7%+1.0%
TTM-8.7%-11.8%+3.1%
YOY-9.0%-11.2%+2.2%
5Y-7.1%-13.2%+6.1%
10Y-2.5%-14.6%+12.1%
1.1.3. Return on Equity

Shows how efficient AC Immune Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -12.3% Return on Equity means AC Immune Ltd generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AC Immune Ltd:

  • The MRQ is -12.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.3%TTM-9.9%-2.5%
TTM-9.9%YOY-9.8%0.0%
TTM-9.9%5Y-7.9%-2.0%
5Y-7.9%10Y-2.4%-5.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.3%-14.0%+1.7%
TTM-9.9%-15.2%+5.3%
YOY-9.8%-14.0%+4.2%
5Y-7.9%-18.8%+10.9%
10Y-2.4%-19.3%+16.9%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of AC Immune Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient AC Immune Ltd is operating .

  • Measures how much profit AC Immune Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AC Immune Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-8.0%+8.0%
TTM-8.0%YOY-467,510.6%+467,502.6%
TTM-8.0%5Y-93,888.4%+93,880.4%
5Y-93,888.4%10Y-49,695.1%-44,193.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--351.1%+351.1%
TTM-8.0%-224.3%+216.3%
YOY-467,510.6%-243.1%-467,267.5%
5Y-93,888.4%-396.3%-93,492.1%
10Y-49,695.1%-510.1%-49,185.0%
1.2.2. Operating Ratio

Measures how efficient AC Immune Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AC Immune Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.557-0.557
TTM0.557YOY8,460.520-8,459.963
TTM0.5575Y1,697.616-1,697.058
5Y1,697.61610Y899.896+797.720
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM0.5573.255-2.698
YOY8,460.5203.484+8,457.036
5Y1,697.6165.004+1,692.612
10Y899.8966.533+893.363
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of AC Immune Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.78 means the company has $7.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AC Immune Ltd:

  • The MRQ is 7.779. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.312. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.779TTM8.312-0.533
TTM8.312YOY11.419-3.107
TTM8.3125Y14.591-6.280
5Y14.59110Y13.424+1.167
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7793.793+3.986
TTM8.3124.052+4.260
YOY11.4194.945+6.474
5Y14.5915.990+8.601
10Y13.4246.326+7.098
1.3.2. Quick Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 10.89 means the company can pay off $10.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AC Immune Ltd:

  • The MRQ is 10.887. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.401. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.887TTM11.401-0.514
TTM11.401YOY17.835-6.433
TTM11.4015Y20.212-8.811
5Y20.21210Y16.355+3.858
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.8873.186+7.701
TTM11.4013.581+7.820
YOY17.8354.803+13.032
5Y20.2125.922+14.290
10Y16.3556.430+9.925
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of AC Immune Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of AC Immune Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AC Immune Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that AC Immune Ltd assets are financed with 13.5% credit (debt) and the remaining percentage (100% - 13.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AC Immune Ltd:

  • The MRQ is 0.135. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.121. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.121+0.014
TTM0.121YOY0.082+0.040
TTM0.1215Y0.096+0.026
5Y0.09610Y0.113-0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1350.330-0.195
TTM0.1210.340-0.219
YOY0.0820.287-0.205
5Y0.0960.368-0.272
10Y0.1130.383-0.270
1.4.2. Debt to Equity Ratio

Measures if AC Immune Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.6% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AC Immune Ltd:

  • The MRQ is 0.156. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.138. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.156TTM0.138+0.018
TTM0.138YOY0.089+0.049
TTM0.1385Y0.106+0.032
5Y0.10610Y0.131-0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1560.366-0.210
TTM0.1380.415-0.277
YOY0.0890.369-0.280
5Y0.1060.441-0.335
10Y0.1310.483-0.352
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of AC Immune Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings AC Immune Ltd generates.

  • Above 15 is considered overpriced but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A PE ratio of -3.64 means the investor is paying $-3.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AC Immune Ltd:

  • The EOD is -4.803. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.636. Based on the earnings, the company is expensive. -2
  • The TTM is -8.648. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.803MRQ-3.636-1.167
MRQ-3.636TTM-8.648+5.012
TTM-8.648YOY-3.632-5.016
TTM-8.6485Y-6.910-1.737
5Y-6.91010Y-41.907+34.996
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.803-2.571-2.232
MRQ-3.636-3.020-0.616
TTM-8.648-2.891-5.757
YOY-3.632-3.549-0.083
5Y-6.910-6.222-0.688
10Y-41.907-6.317-35.590
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AC Immune Ltd:

  • The EOD is 110.698. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 83.802. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 17.006. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD110.698MRQ83.802+26.896
MRQ83.802TTM17.006+66.796
TTM17.006YOY-3.637+20.643
TTM17.0065Y-1.894+18.900
5Y-1.89410Y-3.436+1.542
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD110.698-3.225+113.923
MRQ83.802-3.748+87.550
TTM17.006-3.717+20.723
YOY-3.637-5.046+1.409
5Y-1.894-7.998+6.104
10Y-3.436-8.522+5.086
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of AC Immune Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.80 means the investor is paying $1.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AC Immune Ltd:

  • The EOD is 2.372. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.796. Based on the equity, the company is underpriced. +1
  • The TTM is 2.087. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.372MRQ1.796+0.576
MRQ1.796TTM2.087-0.291
TTM2.087YOY1.349+0.737
TTM2.0875Y2.095-0.008
5Y2.09510Y3.112-1.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3721.936+0.436
MRQ1.7962.247-0.451
TTM2.0872.301-0.214
YOY1.3492.387-1.038
5Y2.0953.666-1.571
10Y3.1124.139-1.027
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AC Immune Ltd.

3.1. Institutions holding AC Immune Ltd

Institutions are holding 29.521% of the shares of AC Immune Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Bvf Inc14.73351.185814571236714285796.1563
2024-03-31Avidity Partners Management LP4.51980.426644700009200.0206
2024-03-31BlackRock Inc2.57030.000225419521239325.1254
2024-03-31Redmile Group, LLC2.02940.2181200703120070310
2024-03-31Morgan Stanley - Brokerage Accounts1.39930.00031383854-373386-21.2484
2024-03-31Wells Fargo & Co1.13220.00081119703-28988-2.5236
2024-03-31Junked Platinum Investment Management Ltd1.10720.13071095026-420559-27.749
2024-03-31Renaissance Technologies Corp0.52150.00245157799820023.5165
2024-03-31Deutsche Bank AG0.25620.000425337500
2024-03-31Handelsbanken Fonder AB0.15170.00191500004893648.4208
2024-03-31Eversept Partners, LLC0.1260.024612458900
2024-03-31LANDSCAPE CAPITAL MANAGEMENT,LLC0.11870.03041174181174180
2024-03-31Assenagon Asset Management SA0.11270.000811141800
2024-03-31SCOGGIN LLC0.08530.085584401844010
2024-03-31Dimensional Fund Advisors, Inc.0.06040.00015975200
2024-03-31Geode Capital Management, LLC0.05540547971388333.9322
2024-03-31Banque Cantonale Vaudoise0.05470.006354134-713-1.3
2024-03-31FMR Inc0.027502720200
2024-03-31UBS Group AG0.0239023665-21335-47.4111
2024-03-31Goldman Sachs Group Inc0.0239023609-10971-31.7264
Total 29.10962.114928788941+8781626+30.5%

3.2. Funds holding AC Immune Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-05-31BlackRock Health Sciences Opps Inv A1.09540.0605108334000
2024-05-31BlackRock Health Sciences Term Trust0.76080.191375239000
2024-06-28iShares Biotechnology ETF0.41940.02254147583860.0932
2024-06-30Handelsbanken Europa Småbolag (A1 SEK)0.37920.7277375000-45000-10.7143
2024-05-31DWS ESG Biotech LC0.25620.267325338100
2024-05-31Monega ARIAD Innovation R0.21190.662220956800
2024-03-31BlackRock Health Sciences0.07910.03727818000
2024-06-28ALPS Medical Breakthroughs ETF0.07820.29657737600
2024-05-31Fidelity Nasdaq Composite Index0.05540.00165479700
2024-06-28iShares Nasdaq US Biotech ETF USD Acc0.05490.03975434400
2024-05-31Pacific Select Health Sciences I0.05370.06055315000
2024-05-31Top Class Healthcare FI0.02830.90272800000
2024-05-31Fidelity Select Biotechnology0.02750.00282720200
2024-05-31DFA US Vector Equity I0.0160.00151582100
2024-05-31DFA US Micro Cap I0.01060.00071053000
2023-12-31China Universal NASDAQ Bio-Tch ETF(QDII)0.00980.043967496740
2024-05-31LUX IM Global Medtech HX0.00970.0194961700
2024-03-31BGF Next Generation Health Care Z2 USD0.0090.1055887500
2024-06-28Invesco NASDAQ Future Gen 200 ETF0.00850.4512844300
2024-05-31DFA US Core Equity 2 I0.00830.0001819700
Total 3.57193.89393532643-34940-1.0%
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of AC Immune Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.191-0.026-87%-0.175-8%-0.056-71%0.043-540%
Book Value Per Share--1.6481.631+1%2.046-19%2.353-30%1.820-9%
Current Ratio--7.7798.312-6%11.419-32%14.591-47%13.424-42%
Debt To Asset Ratio--0.1350.121+11%0.082+65%0.096+41%0.113+19%
Debt To Equity Ratio--0.1560.138+13%0.089+75%0.106+47%0.131+20%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.204-0.156-23%-0.197-3%-0.169-17%-0.080-61%
Free Cash Flow Per Share--0.009-0.124+1508%-0.195+2308%-0.159+1895%-0.079+993%
Free Cash Flow To Equity Per Share--0.001-0.002+311%-0.197+19937%-0.112+11443%0.029-97%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--6.039--------
Intrinsic Value_10Y_min--4.753--------
Intrinsic Value_1Y_max---0.518--------
Intrinsic Value_1Y_min---0.510--------
Intrinsic Value_3Y_max---0.701--------
Intrinsic Value_3Y_min---0.687--------
Intrinsic Value_5Y_max--0.148--------
Intrinsic Value_5Y_min--0.064--------
Market Cap386694683.360+24%294180994.160340695891.360-14%275680672.600+7%488756182.960-40%555862710.164-47%
Net Profit Margin----0.0800%-4688.1090%-941.6110%-498.4450%
Operating Margin----0.0800%-4675.1060%-938.8840%-496.9510%
Operating Ratio---0.557-100%8460.520-100%1697.616-100%899.896-100%
Pb Ratio2.372+24%1.7962.087-14%1.349+33%2.095-14%3.112-42%
Pe Ratio-4.803-32%-3.636-8.648+138%-3.6320%-6.910+90%-41.907+1053%
Price Per Share3.910+24%2.9603.441-14%2.788+6%4.941-40%5.620-47%
Price To Free Cash Flow Ratio110.698+24%83.80217.006+393%-3.637+104%-1.894+102%-3.436+104%
Price To Total Gains Ratio-20.484-32%-15.507-10.052-35%-17.668+14%-23.905+54%-31.044+100%
Quick Ratio--10.88711.401-5%17.835-39%20.212-46%16.355-33%
Return On Assets---0.107-0.087-19%-0.090-16%-0.071-34%-0.025-76%
Return On Equity---0.123-0.099-20%-0.098-20%-0.079-36%-0.024-80%
Total Gains Per Share---0.191-0.026-87%-0.175-8%-0.056-71%0.043-540%
Usd Book Value--163836764.400161456459.600+1%202357615.200-19%232732886.320-30%180003592.200-9%
Usd Book Value Change Per Share---0.191-0.026-87%-0.175-8%-0.056-71%0.043-540%
Usd Book Value Per Share--1.6481.631+1%2.046-19%2.353-30%1.820-9%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.204-0.156-23%-0.197-3%-0.169-17%-0.080-61%
Usd Free Cash Flow--877610.000-12295882.300+1501%-19286187.500+2298%-15679550.120+1887%-7799941.400+989%
Usd Free Cash Flow Per Share--0.009-0.124+1508%-0.195+2308%-0.159+1895%-0.079+993%
Usd Free Cash Flow To Equity Per Share--0.001-0.002+311%-0.197+19937%-0.112+11443%0.029-97%
Usd Market Cap386694683.360+24%294180994.160340695891.360-14%275680672.600+7%488756182.960-40%555862710.164-47%
Usd Price Per Share3.910+24%2.9603.441-14%2.788+6%4.941-40%5.620-47%
Usd Profit---20226928.800-15452164.200-24%-19653085.100-3%-16753914.620-17%-8517883.000-58%
Usd Revenue---4190163.100-100%1113998.500-100%3990351.120-100%7919052.000-100%
Usd Total Gains Per Share---0.191-0.026-87%-0.175-8%-0.056-71%0.043-540%
 EOD+4 -4MRQTTM+11 -20YOY+11 -205Y+9 -2410Y+7 -26

4.2. Fundamental Score

Let's check the fundamental score of AC Immune Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.803
Price to Book Ratio (EOD)Between0-12.372
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.887
Current Ratio (MRQ)Greater than17.779
Debt to Asset Ratio (MRQ)Less than10.135
Debt to Equity Ratio (MRQ)Less than10.156
Return on Equity (MRQ)Greater than0.15-0.123
Return on Assets (MRQ)Greater than0.05-0.107
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of AC Immune Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.570
Ma 20Greater thanMa 503.691
Ma 50Greater thanMa 1003.917
Ma 100Greater thanMa 2003.393
OpenGreater thanClose3.950
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in CHF. All numbers in thousands.

Summary
Total Assets167,281
Total Liabilities22,600
Total Stockholder Equity144,681
 As reported
Total Liabilities 22,600
Total Stockholder Equity+ 144,681
Total Assets = 167,281

Assets

Total Assets167,281
Total Current Assets109,873
Long-term Assets57,408
Total Current Assets
Cash And Cash Equivalents 57,009
Short-term Investments 47,812
Net Receivables 1,135
Inventory -868
Other Current Assets 4,785
Total Current Assets  (as reported)109,873
Total Current Assets  (calculated)109,873
+/-0
Long-term Assets
Property Plant Equipment 6,577
Long Term Investments 415
Intangible Assets 50,416
Long-term Assets  (as reported)57,408
Long-term Assets  (calculated)57,408
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,124
Long-term Liabilities8,476
Total Stockholder Equity144,681
Total Current Liabilities
Short-term Debt 672
Accounts payable 2,837
Other Current Liabilities 10,541
Total Current Liabilities  (as reported)14,124
Total Current Liabilities  (calculated)14,050
+/- 74
Long-term Liabilities
Capital Lease Obligations 3,329
Long-term Liabilities  (as reported)8,476
Long-term Liabilities  (calculated)3,329
+/- 5,147
Total Stockholder Equity
Common Stock2,093
Retained Earnings -332,558
Accumulated Other Comprehensive Income -35
Other Stockholders Equity 475,181
Total Stockholder Equity (as reported)144,681
Total Stockholder Equity (calculated)144,681
+/-0
Other
Capital Stock2,093
Cash and Short Term Investments 104,821
Common Stock Shares Outstanding 99,385
Current Deferred Revenue74
Liabilities and Stockholders Equity 167,281
Net Debt -53,680
Net Invested Capital 144,681
Net Working Capital 95,749
Property Plant and Equipment Gross 17,962
Short Long Term Debt Total 3,329



Balance Sheet

Currency in CHF. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
30,497
0
0
55,100
79,931
73,545
103,282
160,683
156,100
144,599
131,288
125,441
132,013
120,014
112,556
208,724
196,556
312,892
296,222
315,349
299,250
288,232
273,258
256,610
238,740
227,959
211,090
203,396
261,443
235,519
216,786
205,557
185,938
169,150
156,228
142,986
182,814
167,281
167,281182,814142,986156,228169,150185,938205,557216,786235,519261,443203,396211,090227,959238,740256,610273,258288,232299,250315,349296,222312,892196,556208,724112,556120,014132,013125,441131,288144,599156,100160,683103,28273,54579,93155,1000030,497
   > Total Current Assets 
29,667
0
0
54,500
79,346
72,813
102,529
159,683
154,894
142,389
128,759
122,781
129,534
116,450
108,881
205,197
192,928
306,936
290,346
309,450
292,774
282,020
267,144
250,589
231,767
220,489
202,802
195,376
202,634
177,058
158,380
147,602
128,094
111,688
99,152
86,179
125,153
109,873
109,873125,15386,17999,152111,688128,094147,602158,380177,058202,634195,376202,802220,489231,767250,589267,144282,020292,774309,450290,346306,936192,928205,197108,881116,450129,534122,781128,759142,389154,894159,683102,52972,81379,34654,5000029,667
       Cash And Cash Equivalents 
3,328
0
0
53,700
76,522
67,860
82,377
157,592
152,210
138,084
124,180
117,210
124,377
109,669
102,664
199,122
156,462
222,138
205,735
212,457
193,587
182,860
177,464
176,567
160,893
151,092
104,135
93,584
82,216
57,835
63,147
44,503
31,586
57,434
40,007
31,927
78,494
57,009
57,00978,49431,92740,00757,43431,58644,50363,14757,83582,21693,584104,135151,092160,893176,567177,464182,860193,587212,457205,735222,138156,462199,122102,664109,669124,377117,210124,180138,084152,210157,59282,37767,86076,52253,700003,328
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
80,000
80,000
90,000
95,000
95,000
85,000
70,000
65,000
65,000
95,000
95,000
116,000
116,000
91,000
96,000
91,000
48,000
53,000
48,000
24,554
47,812
47,81224,55448,00053,00048,00091,00096,00091,000116,000116,00095,00095,00065,00065,00070,00085,00095,00095,00090,00080,00080,00030,0000000000000000000
       Net Receivables 
25,980
0
0
200
316
1,762
15,880
1,259
1,406
2,022
2,615
3,587
3,717
4,243
3,044
3,390
4,102
1,798
1,694
3,996
1,399
741
991
1,258
1,920
1,067
941
433
1,403
418
768
4,211
800
816
978
718
15,668
1,135
1,13515,6687189788168004,2117684181,4034339411,0671,9201,2589917411,3993,9961,6941,7984,1023,3903,0444,2433,7173,5872,6152,0221,4061,25915,8801,7623162000025,980
       Other Current Assets 
375
0
0
600
2,508
3,191
4,272
832
1,278
2,283
1,964
1,984
1,440
2,538
3,173
2,685
2,364
3,000
2,917
2,997
2,788
3,419
3,689
2,764
3,954
3,330
2,726
6,359
3,015
2,805
3,800
2,888
4,708
6,036
5,470
5,940
7,059
4,785
4,7857,0595,9405,4706,0364,7082,8883,8002,8053,0156,3592,7263,3303,9542,7643,6893,4192,7882,9972,9173,0002,3642,6853,1732,5381,4401,9841,9642,2831,2788324,2723,1912,50860000375
   > Long-term Assets 
0
0
0
600
585
732
753
1,000
1,206
2,210
2,529
2,660
2,479
3,564
3,675
3,527
3,628
5,956
5,876
5,899
6,476
6,212
6,114
6,021
6,973
7,470
8,288
8,020
58,809
58,461
58,406
57,955
57,844
57,462
57,076
56,807
57,661
57,408
57,40857,66156,80757,07657,46257,84457,95558,40658,46158,8098,0208,2887,4706,9736,0216,1146,2126,4765,8995,8765,9563,6283,5273,6753,5642,4792,6602,5292,2101,2061,000753732585600000
       Property Plant Equipment 
547
0
0
600
500
647
668
915
1,120
2,084
2,403
2,534
2,353
3,354
3,465
3,317
3,324
5,652
5,572
5,595
6,172
5,908
5,810
5,717
6,639
7,043
7,864
7,626
8,030
7,682
7,629
7,178
7,067
6,685
6,299
6,030
6,884
6,577
6,5776,8846,0306,2996,6857,0677,1787,6297,6828,0307,6267,8647,0436,6395,7175,8105,9086,1725,5955,5725,6523,3243,3173,4653,3542,3532,5342,4032,0841,12091566864750060000547
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
126
220
0
0
0
304
304
304
304
304
304
304
0
334
363
363
363
363
361
361
361
361
361
361
361
415
4153613613613613613613613633633633633340304304304304304304304000220126000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233,243
0
0
0
0
50,416
0
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,416
50,41650,41650,41650,41650,41650,41650,41650,416050,4160000233,24300000000000000000000000
       Long-term Assets Other 
0
0
0
-100
85
-32
47
0
-6
-10
-29
-60
21
-64
25
0
0
2,082
5,876
5,899
6,476
6,212
0
304
334
93
61
31
363
50,416
-58,045
-57,594
361
-57,101
-56,715
-56,446
361
415
415361-56,446-56,715-57,101361-57,594-58,04550,41636331619333430406,2126,4765,8995,8762,0820025-6421-60-29-10-6047-3285-100000
> Total Liabilities 
6,874
0
0
7,000
8,888
8,866
12,740
14,474
13,720
11,545
10,396
12,769
15,174
14,186
17,163
16,748
18,933
71,038
22,932
22,966
26,808
22,631
22,396
23,367
23,262
20,543
21,808
24,175
29,464
21,388
13,974
15,503
16,947
16,215
16,900
17,322
22,171
22,600
22,60022,17117,32216,90016,21516,94715,50313,97421,38829,46424,17521,80820,54323,26223,36722,39622,63126,80822,96622,93271,03818,93316,74817,16314,18615,17412,76910,39611,54513,72014,47412,7408,8668,8887,000006,874
   > Total Current Liabilities 
4,448
0
0
3,700
6,101
5,875
9,544
11,012
9,922
7,657
5,962
8,226
9,754
8,578
11,281
10,681
13,082
60,710
13,260
14,012
17,510
13,252
12,947
13,847
14,018
11,125
11,847
14,223
20,026
11,911
11,924
13,600
11,481
10,755
11,153
11,710
13,576
14,124
14,12413,57611,71011,15310,75511,48113,60011,92411,91120,02614,22311,84711,12514,01813,84712,94713,25217,51014,01213,26060,71013,08210,68111,2818,5789,7548,2265,9627,6579,92211,0129,5445,8756,1013,700004,448
       Short-term Debt 
0
0
0
0
0
0
4,719
6,768
0
0
386
392
395
455
0
0
332
47,535
749
760
1,094
759
759
751
443
441
571
577
570
573
577
581
548
551
553
555
672
672
6726725555535515485815775735705775714414437517597591,09476074947,53533200455395392386006,7684,719000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
386
392
395
455
841
0
358
47,119
329
334
652
324
321
441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000044132132465233432947,11935808414553953923860000000000
       Accounts payable 
1,595
0
0
900
1,719
994
2,625
2,832
4,035
2,641
954
1,361
1,092
1,182
2,015
515
1,979
829
156
0
142
760
1,442
1,020
2,184
370
317
215
2,003
501
337
1,519
929
1,136
1,352
1,479
1,679
2,837
2,8371,6791,4791,3521,1369291,5193375012,0032153173702,1841,0201,44276014201568291,9795152,0151,1821,0921,3619542,6414,0352,8322,6259941,719900001,595
       Other Current Liabilities 
2,853
0
0
2,800
4,337
3,728
4,825
6,874
5,366
4,888
4,667
6,825
8,307
7,355
8,798
10,124
20,840
8,800
16,828
8,551
23,594
9,281
18,678
21,992
22,170
19,468
21,222
26,616
33,472
10,571
10,585
10,976
9,417
8,653
8,818
9,338
11,087
10,541
10,54111,0879,3388,8188,6539,41710,97610,58510,57133,47226,61621,22219,46822,17021,99218,6789,28123,5948,55116,8288,80020,84010,1248,7987,3558,3076,8254,6674,8885,3666,8744,8253,7284,3372,800002,853
   > Long-term Liabilities 
0
0
0
3,300
2,787
2,991
3,196
3,462
3,798
3,888
4,434
4,543
5,420
5,608
5,882
6,067
5,851
10,328
9,672
8,954
9,298
9,379
9,449
9,520
9,244
9,418
9,961
9,952
9,438
9,477
2,050
1,903
5,466
5,460
5,747
5,612
8,595
8,476
8,4768,5955,6125,7475,4605,4661,9032,0509,4779,4389,9529,9619,4189,2449,5209,4499,3799,2988,9549,67210,3285,8516,0675,8825,6085,4204,5434,4343,8883,7983,4623,1962,9912,7873,300000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
602
197
1,891
1,815
1,764
1,813
1,713
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,7131,8131,7641,8151,891197602000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-4,719
-6,768
0
0
-386
-392
-395
-455
0
0
-332
-45,453
1,230
1,133
1,161
1,389
1,281
1,050
1,780
1,706
2,126
1,992
2,340
2,196
2,050
1,903
2,253
2,115
1,976
1,838
2,825
2,657
2,6572,8251,8381,9762,1152,2531,9032,0502,1962,3401,9922,1261,7061,7801,0501,2811,3891,1611,1331,230-45,453-33200-455-395-392-38600-6,768-4,719000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,666
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,66600000000000000000
> Total Stockholder Equity
23,623
0
0
48,200
71,043
64,679
90,542
146,209
142,380
133,054
120,892
112,672
116,839
105,828
95,393
191,976
177,623
241,854
273,290
292,383
272,442
265,601
250,862
233,243
215,478
207,416
189,282
179,221
231,979
214,131
202,812
190,054
168,991
152,935
139,328
125,664
160,643
144,681
144,681160,643125,664139,328152,935168,991190,054202,812214,131231,979179,221189,282207,416215,478233,243250,862265,601272,442292,383273,290241,854177,623191,97695,393105,828116,839112,672120,892133,054142,380146,20990,54264,67971,04348,2000023,623
   Common Stock
174
0
0
900
928
928
988
1,126
1,135
1,139
1,142
1,143
1,147
1,147
1,149
1,351
1,351
1,361
1,436
1,436
1,437
1,437
1,438
1,539
1,538
1,539
1,539
1,589
1,794
1,795
1,796
1,797
1,797
1,797
1,800
1,802
2,089
2,093
2,0932,0891,8021,8001,7971,7971,7971,7961,7951,7941,5891,5391,5391,5381,5391,4381,4371,4371,4361,4361,3611,3511,3511,1491,1471,1471,1431,1421,1391,1351,12698892892890000174
   Retained Earnings Total Equity00000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,900
0
0
0
-2,200
-2,200
0
0
0
0
0
0
0
-3,836
-3,958
-4,165
-4,528
-4,896
-5,262
0
-5,717
-6,148
-6,623
0
0
0
49
72
10
2
-6
5
-51
-35
-35-515-62107249000-6,623-6,148-5,7170-5,262-4,896-4,528-4,165-3,958-3,8360000000-2,200-2,200000-1,9000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,985
315,232
298,259
346,024
346,479
346,526
346,568
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000346,568346,526346,479346,024298,259315,232302,985000000000000000
   Treasury Stock00000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
83,100
110,496
110,453
123,379
187,995
188,166
188,191
188,207
188,215
188,299
188,357
188,407
298,077
298,149
298,259
346,024
346,479
346,526
346,568
346,634
346,742
346,790
354,651
354,814
359,297
431,127
431,129
431,136
431,179
431,199
431,241
433,589
434,345
474,802
475,181
475,181474,802434,345433,589431,241431,199431,179431,136431,129431,127359,297354,814354,651346,790346,742346,634346,568346,526346,479346,024298,259298,149298,077188,407188,357188,299188,215188,207188,191188,166187,995123,379110,453110,49683,100000



Balance Sheet

Currency in CHF. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.




Income Statement

Currency in CHF. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue14,801
Cost of Revenue-54,606
Gross Profit-39,805-39,805
 
Operating Income (+$)
Gross Profit-39,805
Operating Expense-68,425
Operating Income-53,624-108,230
 
Operating Expense (+$)
Research Development54,606
Selling General Administrative10,576
Selling And Marketing Expenses0
Operating Expense68,42565,182
 
Net Interest Income (+$)
Interest Income1,044
Interest Expense-176
Other Finance Cost-0
Net Interest Income868
 
Pretax Income (+$)
Operating Income-53,624
Net Interest Income868
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-54,223-52,157
EBIT - interestExpense = -52,756
-54,223
-54,057
Interest Expense176
Earnings Before Interest and Taxes (EBIT)-52,580-54,047
Earnings Before Interest and Taxes (EBITDA)-50,365
 
After tax Income (+$)
Income Before Tax-54,223
Tax Provision-10
Net Income From Continuing Ops-54,233-54,233
Net Income-54,233
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,425
Total Other Income/Expenses Net-1,467-868
 

Technical Analysis of AC Immune Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AC Immune Ltd. The general trend of AC Immune Ltd is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AC Immune Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AC Immune Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.99 < 4.9782 < 5.14.

The bearish price targets are: 3.44 > 3.42 > 3.42.

Tweet this
AC Immune Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AC Immune Ltd. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AC Immune Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AC Immune Ltd. The current macd is -0.03734049.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the AC Immune Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for AC Immune Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the AC Immune Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
AC Immune Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAC Immune Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AC Immune Ltd. The current adx is 12.59.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy AC Immune Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
AC Immune Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AC Immune Ltd. The current sar is 3.4524.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AC Immune Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AC Immune Ltd. The current rsi is 54.57. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
AC Immune Ltd Daily Relative Strength Index (RSI) ChartAC Immune Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AC Immune Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the AC Immune Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
AC Immune Ltd Daily Stochastic Oscillator ChartAC Immune Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AC Immune Ltd. The current cci is 115.19.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
AC Immune Ltd Daily Commodity Channel Index (CCI) ChartAC Immune Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AC Immune Ltd. The current cmo is 16.82.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
AC Immune Ltd Daily Chande Momentum Oscillator (CMO) ChartAC Immune Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AC Immune Ltd. The current willr is -28.98550725.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that AC Immune Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AC Immune Ltd Daily Williams %R ChartAC Immune Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AC Immune Ltd.

AC Immune Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AC Immune Ltd. The current atr is 0.25643047.

AC Immune Ltd Daily Average True Range (ATR) ChartAC Immune Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AC Immune Ltd. The current obv is 81,740,603.

AC Immune Ltd Daily On-Balance Volume (OBV) ChartAC Immune Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AC Immune Ltd. The current mfi is 70.86.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
AC Immune Ltd Daily Money Flow Index (MFI) ChartAC Immune Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AC Immune Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-31BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

AC Immune Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AC Immune Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.570
Ma 20Greater thanMa 503.691
Ma 50Greater thanMa 1003.917
Ma 100Greater thanMa 2003.393
OpenGreater thanClose3.950
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of AC Immune Ltd with someone you think should read this too:
  • Are you bullish or bearish on AC Immune Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AC Immune Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AC Immune Ltd

I send you an email if I find something interesting about AC Immune Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about AC Immune Ltd.

Receive notifications about AC Immune Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.